OncoMatch/Clinical Trials/NCT04719156

Fluorescent Intra-operative Tumor Margin Examination

Is NCT04719156 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Indocyanine green solution administered at 2.0mg/kg. and Stryker SPY-PHI Imaging Device for sarcoma.

Treatment: Indocyanine green solution administered at 2.0mg/kg. · Stryker SPY-PHI Imaging Device — Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.